Current breast cancer prevention with selective estrogen receptor modulators (SERM) and aromatase inhibitors decreases the risk of estrogen-receptor (ER) positive breast cancer sub-types, but not those without ER expression3–5. Here, ESR1 is linked to breast carcinoma.